Wild type transthyretin cardiac amyloidosis (wtATTR) and heart failure with reduced ejection fraction (HFrEF): can angiotensin receptor/neprilysin inhibitors be a therapeutic option?
Event:
Heart Failure 2023
Topic:
Myocardial Disease
Session:
Myocardial disease 2
